• Users Online: 132
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 39  |  Issue : 1  |  Page : 13-19

Evaluation of multidrug resistance in acute leukemia using real-time polymerase chain reaction


Oncological Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt

Correspondence Address:
Eman Ahmed Hasan
South Egypt Cancer Institute, Assiut University, Assiut, 71515
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-1067.124839

Rights and Permissions

Background Despite the advances in the cure rate for acute leukemia, ~25% of affected patients develop relapses. Expression of genes for the multidrug resistance (MDR1) and breast cancer-resistance protein (BCRP) may confer the phenotype of resistance to the treatment of acute leukemia. Objective To analyze the expression of the MDR1 and BCRP genes in new cases of acute leukemia using real-time PCR (RT-PCR) and to determine the correlation between their expression and overall survival (OS). Patients and methods Patients diagnosed with acute myeloblastic leukemia (AML) (n = 15) and acute lymphoblastic leukemia (ALL) (n = 35), and 20 blood donors as a control group were included in this study. The expressions of mRNA for the MDR1 and BCRP genes were assessed by RT-PCR. Myeloid surface markers such as CD34, CD33, CD13, and CD14 and lymphoid surface markers such as CD3, CD5, CD2, CD4, CD8, and CD19 were analyzed using flow cytometry. Results The groups with the MDR gene and the BCRP gene showed a highly significant difference compared with the control group (P < 0.000). The relation between MDR and BCRP in both AML and ALL groups showed no significant difference. There was a significant difference between BCRP expression in the AML and ALL groups (P < 0.01). There was no significant difference in the OS between MDR+ cases and MDR- cases in the AML and ALL groups. In contrast, the OS in BCRP+ cases and BCRP- cases showed a significant difference between AML and ALL groups (P < 0.01). No significant difference was detected between OS in AML (MDR+, CD34+) and AML (MDR+, CD34−). In contrast, OS between AML (BCRP+, CD34+) and AML (BCRP+, CD34−) showed a significant difference (P < 0.01). The difference between OS in ALL (MDR+, CD34+) and ALL (MDR+, CD34−) was not significant. In contrast, a significant difference was detected between OS in ALL (BCRP+, CD34+) and ALL (BCRP+, CD34−) (P < 0.01). OS in the AML group that was BCRP+ (CD13+) showed a significant difference (P < 0.01). In the ALL group, the association between MDR+ and CD19+ or BCRP+ and CD19+ did not affect the survival significantly. Conclusion We concluded that the evaluation of the expression of genes for resistance to antineoplastic drugs in acute leukemia upon diagnosis, and particularly the expression of the BCRP gene, may be of clinical relevance.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed995    
    Printed23    
    Emailed0    
    PDF Downloaded85    
    Comments [Add]    

Recommend this journal